Please note that assistive links (commonly known as "skip to links") are used throughout this site. These links are not well-supported by some mobile devices. If you are encountering difficulty using these links, please navigate around these links, or access the site on a desktop browser.
Skip to the primary content of this page Skip to the footer of this page
Provident Healthcare Partners Provident Healthcare Partners

Q1 2025 Pharma Services Update

Provident Healthcare Partners
Skip to the end of the Expertise Menu

Q1 2025 Pharma Services Update

M&A activity across the outsourced pharmaceutical services landscape remained active in Q1 2025, though trends varied by subsector. CRO transactions continued at a healthy pace, driven by growing R&D investment from pharmaceutical companies and heightened interest in platforms with therapeutic expertise. Strategic acquisitions like InTandem’s purchase of Clinilabs and Blackstone’s investment in CMIC underscore buyers’ focus on scaling specialized capabilities.

Meanwhile, M&A activity in the SMO sector slowed from 2024 levels as newly formed site networks prioritized integration efforts, though add-on acquisitions and new platform opportunities are expected to pick up in the coming quarters. In the pharmaceutical commercialization space, deal volume remained steady, with 14 closed transactions, and strong investor demand for differentiated, high-science platforms is expected to sustain momentum despite broader market headwinds.

To print and download the full Pharma Services Update report, please click below…

[holo_button icon=”/wp-content/uploads/2025/04/Pharma-Services-Q12025.pdf”” color=”#003561″ target=”blank”]PRINT/DOWNLOAD[/holo_button]